Amsino receives FDA approval for hydrophillic intermittent catheters
Pomona, Ca — Amsino Medical Group announces FDA approval via a 510(k) for hydrophilic intermittent urology catheters and kits. The products are complimentary to the Amsino portfolio of urological products and utilize existing coating technologies and expertise. The hydrophilic coating will be combined with Amsino’s R-Polished® technology to a provide a superior product for self-catheterization and clinical use.
Dr. Richard Lee, Chairman and CEO of Amsino stated “Hydrophilic intermittent catheters and kits are important additions to our product portfolio. The products are important for Amsino’s strategy to support business growth in the dynamic homecare and other non-acute markets.”
Hydrophilic coatings have proven to reduce urethral irritation and trauma. This results in better patient outcomes and comfort. The kits include a self-activated water sachet that reduces the chance of catheter surface contamination while offering efficiency and convenience for the user.
This approval will enable Amsino to develop and expand the urological portfolio with innovative future products. The company will drive product decisions with a customer first/customer focused strategy with emphasis on solving healthcare problems.